title: Absence of prenatal developmental toxicity from inhaled arsenic trioxide in rats.
abstract: A review of the literature revealed no published inhalational developmental toxicity studies of arsenic performed according to modern regulatory guidelines and with exposure throughout gestation. In the present study, inorganic arsenic, as arsenic trioxide (As(+3), As2O3), was administered via whole-body inhalational exposure to groups of twenty-five Crl:CD(SD)BR female rats for six h per day every day, beginning fourteen days prior to mating and continuing throughout mating and gestation. Exposures were begun prior to mating in order to achieve a biological steady state of As(+3) in the dams prior to embryonal-fetal development. In a preliminary exposure range-finding study, half of the females that had been exposed to arsenic trioxide at 25 mg/m3 died or were euthanized in extremis. In the definitive study, target exposure levels were 0.3, 3.0, and 10.0 mg/m3. Maternal toxicity, which was determined by the occurrence of rales, a decrease in net body weight gain, and a decrease in food intake during pre-mating and gestational exposure, was observed only at the 10 mg/m3 exposure level. Intrauterine parameters (mean numbers of corpora lutea, implantation sites, resorptions and viable fetuses, and mean fetal weights) were unaffected by treatment. No treatment-related malformations or developmental variations were noted at any exposure level. The no-observed-adverse-effect level (NOAEL) for maternal toxicity was 3.0 mg/m3; the NOAEL for developmental toxicity was greater than or equal to 10 mg/m3, 760 times both the time-weighted average threshold limit value (TLV) and the permissible exposure limit (PEL) for humans. Based on the results of this study, we conclude that arsenic trioxide, when administered via whole-body inhalation to pregnant rats, is not a developmental toxicant.
authors.affiliation: WIL Research Laboratories, Inc., Ashland, Ohio 44805, USA.
authors.forename: J F
authors.initials: JF
authors.lastname: Holson
authors.forename: D G
authors.initials: DG
authors.lastname: Stump
authors.forename: C E
authors.initials: CE
authors.lastname: Ulrich
authors.forename: C H
authors.initials: CH
authors.lastname: Farr
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000280:Administration, Inhalation; D000818:Animals; D020261:Arsenic Poisoning; D000077237:Arsenic Trioxide; D001152:Arsenicals; D001273:Atmosphere Exposure Chambers; D001835:Body Weight / Q000187:drug effects; D001842:Bone and Bones / Q000002:abnormalities / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D004781:Environmental Exposure; D005260:Female; D005333:Fetus / Q000002:abnormalities / Q000187:drug effects; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D010087:Oxides / Q000633:toxicity*; D010865:Pilot Projects; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012098:Reproduction / Q000187:drug effects; D012135:Respiratory Sounds / Q000187:drug effects; D018570:Risk Assessment; D018675:Toxicity Tests
chemical_list: D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide